Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote & News

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 742 8466

Website: www.phathompharma.com

Address:

100 Campus Drive, Suite 102, Florham Park, United States

Joe_90_ Jun. 4 at 6:56 PM

$PHAT algos only trying to shake the leaves

1 · Reply

fgggggggg Jun. 4 at 5:10 PM

$PHAT BULLISH AF!

0 · Reply

yekoiob Jun. 4 at 2:02 PM

$PHAT https://www.ccjm.org/content/93/6/341

0 · Reply

OnlyFibs Jun. 3 at 9:34 PM

$PHAT is in "show me" mode. The stock is testing key support after a steep decline, and while the analyst sentiment remains heavily bullish, the price action needs to prove it. I’m playing this level-to-level—don't try to front-run the bottom, just let the volume and the chart give us the confirmation we need! 💎 🐂 Bull Level: Sustained momentum over $10.50 is the key to unlocking the next leg up to $12.00. 🐻 Bear Level: If $8.75 gives way, the selling pressure will likely accelerate toward fresh lows. #PHAT #Stocks #Trading #hovdid

1 · Reply

Panc Jun. 3 at 7:34 PM

$PHAT added more

0 · Reply

Withermania Jun. 3 at 4:50 PM

$PHAT these conferences are solid but the numbers need to do the talking. Continue to Show the revenue growth, script growth, market expansion, etc. These analysts ask the most generic questions that don’t really highlight how powerful this drug is.

1 · Reply

fgggggggg Jun. 3 at 2:53 PM

$PHAT I'd trust the 925k shares that Perceptive picked up per their 13F

0 · Reply

fgggggggg Jun. 3 at 2:16 PM

$PHAT Another conference today. BULLISH AF

0 · Reply

fgggggggg Jun. 2 at 8:01 PM

$PHAT Nice close. BULLISH AF

0 · Reply

StardustTrader Jun. 2 at 7:11 PM

$PHAT perceptive back after 5/29 13F.

1 · Reply

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

2026-05-26T19:00:09.000Z - 9 days ago

Needham pharmaceuticals analysts hold analyst/industry conference call

May 22, 2026, 8:00 AM EDT - 13 days ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

May 20, 2026, 8:00 AM EDT - 15 days ago

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

May 1, 2026, 8:00 AM EDT - 4 weeks ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

2026-04-30T12:05:31.000Z - 5 weeks ago

Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)

2026-04-30T12:02:20.000Z - 5 weeks ago

Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Phathom Pharmaceuticals Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Phathom Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Phathom Pharmaceuticals Slides: Q1 2026

Apr 30, 2026, 6:59 AM EDT - 5 weeks ago

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 20, 2026, 8:00 AM EDT - 6 weeks ago

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Apr 15, 2026, 1:30 PM EDT - 7 weeks ago

Phathom Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:00 AM EDT - 2 months ago

Phathom Pharmaceuticals Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 2 months ago

Phathom Pharmaceuticals Proxy statement: Proxy filing

2026-03-27T09:00:23.000Z - 2 months ago

Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

2026-03-23T18:25:38.000Z - 2 months ago

Phathom Pharmaceuticals management to meet with Cantor

Mar 11, 2026, 3:30 PM EDT - 3 months ago

Phathom Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 2, 2026, 10:30 AM EST - 3 months ago

Phathom Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-27T12:39:13.000Z - 3 months ago

Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim

2026-02-26T23:40:20.000Z - 3 months ago

Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

Feb 26, 2026, 8:00 AM EST - 3 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 3 months ago

Phathom Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 3 months ago

Phathom Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 3 months ago

Phathom Pharmaceuticals Slides: Q4 2025

2026-02-26T12:06:11.000Z - 3 months ago

Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)

2026-02-26T12:05:14.000Z - 3 months ago

Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

Feb 26, 2026, 7:00 AM EST - 3 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 17, 2026, 8:00 AM EST - 3 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Feb 12, 2026, 11:30 AM EST - 4 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 4 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

2026-01-08T11:31:01.000Z - 5 months ago

Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00

Jan 7, 2026, 10:33 PM EST - 5 months ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-01-07T21:10:45.000Z - 5 months ago

Phathom Pharmaceuticals announces common stock offering, no amount given

2026-01-07T21:05:43.000Z - 5 months ago

Phathom Pharmaceuticals files automatic mixed securities shelf

2026-01-07T21:05:23.000Z - 5 months ago

Phathom Pharmaceuticals sees Q4 revenue $57M-$58M, consensus $56.16M

Jan 7, 2026, 4:05 PM EST - 5 months ago

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:01 PM EST - 5 months ago

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Jan 7, 2026, 7:00 AM EST - 5 months ago

Phathom Pharmaceuticals Slides: Corporate presentation

2025-12-11T21:16:52.000Z - 6 months ago

Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James

2025-12-08T21:30:59.000Z - 6 months ago

Phathom Pharmaceuticals initiated with an Equal Weight at Barclays

Dec 2, 2025, 3:25 PM EST - 6 months ago

Phathom Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 18, 2025, 9:30 AM EST - 7 months ago

Phathom Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:40 PM EST - 7 months ago

Phathom Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 3:00 PM EST - 7 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-04T13:16:14.000Z - 7 months ago

Phathom announces first patient dosed in Phase 2 pHalcon-EoE-201 trial

Nov 4, 2025, 8:00 AM EST - 7 months ago

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Quarterly report: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Earnings release: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Slides: Q3 2025

Oct 30, 2025, 7:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 25, 2025, 9:59 AM EDT - 7 months ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Oct 23, 2025, 8:00 AM EDT - 8 months ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Oct 20, 2025, 8:00 AM EDT - 8 months ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Oct 6, 2025, 8:00 AM EDT - 8 months ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Sep 8, 2025, 1:00 PM EDT - 9 months ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:10 AM EDT - 9 months ago

Phathom Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 20, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 6:59 AM EDT - 10 months ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 28, 2025, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Slides: Corporate Presentation

Jun 23, 2025, 4:15 PM EDT - 1 year ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 7:59 AM EDT - 1 year ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 11, 2025, 10:40 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 12:27 PM EDT - 1 year ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Jun 5, 2025, 9:55 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 11:30 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: AGM 2025

May 20, 2025, 4:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings release: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Slides: Q1 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

May 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Slides: Corporate Presentation

Apr 28, 2025, 7:59 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Apr 8, 2025, 10:15 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Leadership Succession

Mar 31, 2025, 7:59 AM EDT - 1 year ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings release: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Slides: Q4 2024

Mar 6, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Feb 6, 2025, 10:00 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Dec 11, 2024, 12:00 PM EST - 1 year ago

Phathom Pharmaceuticals Slides: Corporate Presentation

Dec 11, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Dec 3, 2024, 2:10 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 1:15 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 9:30 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Slides: Q3 2024

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 27, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Sep 9, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Phathom Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings release: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 18, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jun 11, 2024, 2:40 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 12:30 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference

May 23, 2024, 10:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: AGM 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Quarterly report: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings release: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Slides: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 10, 2024, 9:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Mar 7, 2024, 8:30 AM EST - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

Phathom Pharmaceuticals Annual report: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

Phathom Pharmaceuticals Earnings release: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

Phathom Pharmaceuticals Slides: Q4 2023

Mar 7, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Feb 7, 2024, 1:30 PM EST - 2 years ago

Phathom Pharmaceuticals Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 31, 2024, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 18, 2023, 11:00 AM EST - 2 years ago

Phathom Pharmaceuticals Slides: Investor Presentation

Dec 6, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Nov 29, 2023, 4:15 PM EST - 2 years ago

Phathom Pharmaceuticals Transcript: 6th Annual ISI HealthCONx Conference

Nov 28, 2023, 8:00 AM EST - 2 years ago

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Joe_90_ Jun. 4 at 6:56 PM

$PHAT algos only trying to shake the leaves

1 · Reply

fgggggggg Jun. 4 at 5:10 PM

$PHAT BULLISH AF!

0 · Reply

yekoiob Jun. 4 at 2:02 PM

$PHAT https://www.ccjm.org/content/93/6/341

0 · Reply

OnlyFibs Jun. 3 at 9:34 PM

1 · Reply

Panc Jun. 3 at 7:34 PM

$PHAT added more

0 · Reply

Withermania Jun. 3 at 4:50 PM

1 · Reply

fgggggggg Jun. 3 at 2:53 PM

$PHAT I'd trust the 925k shares that Perceptive picked up per their 13F

0 · Reply

fgggggggg Jun. 3 at 2:16 PM

$PHAT Another conference today. BULLISH AF

0 · Reply

fgggggggg Jun. 2 at 8:01 PM

$PHAT Nice close. BULLISH AF

0 · Reply

StardustTrader Jun. 2 at 7:11 PM

$PHAT perceptive back after 5/29 13F.

1 · Reply

TheFlyingDutchmann Jun. 2 at 4:27 PM

$PHAT weird how they almost closed the gap. Went to 8.78 instead of 8.72. Is it going to go down once more?

3 · Reply

GSTX7 Jun. 2 at 4:14 PM

$PHAT I bought much in the 8's. Mucho much.

0 · Reply

Panc Jun. 2 at 3:23 PM

$PHAT added a lot today

0 · Reply

Withermania Jun. 2 at 2:49 PM

$PHAT could it be they walked it down to stop loss hunt all the way down to right after post orange book update? Seems like this may have been orchestrated. Buy buy buy

0 · Reply

JP2024 Jun. 2 at 1:40 PM

$PHAT today we finish green i just wanted to post that no rhyme nor reason just hoping for a positive day

0 · Reply

fgggggggg Jun. 2 at 1:36 PM

$PHAT don’t be fooled. Fake trading. Nothing has changed. Profitability <60 days away. BULLISH AF!!

1 · Reply

Walleyeslayer Jun. 2 at 1:35 PM

$PHAT What is that old song... "If I had a million dollars".... I buy so much PHAT my cholesterol would go up! Haha. Hoping I'll get another monthly buy at these levels. Wowzer.

0 · Reply

Randy_Lahey_Trevor_Corey Jun. 2 at 1:33 PM

$PHAT officially in panic mode

1 · Reply

scwillia Jun. 2 at 12:20 PM

$PHAT They will exceed 74m consensus for Q2. We have 77m. Bear in mind that net revenue - which is what they report - will benefit from an additional $17-20M this year and, commensurately, COGS will inflate by $17-20M. The Q2 'benefit' will be c.$4.7M, taking revenue from a like-for-like $72M informed by the scrip data to nearer $77M i.e. they're going to BEAT consensus.

0 · Reply

StardustTrader Jun. 1 at 10:02 PM

$PHAT until i see tute postioning change, there is no need to be concerned. Adding in single digits. This is an investment, not a trade.

1 · Reply

Joe_90_ Jun. 1 at 9:48 PM

$PHAT “The best men are not those who have waited for chances but who have taken them; besieged the chance; conquered the chance; and made chance the servitor.” —E.H. Chapin" be ready for the reversal folks

0 · Reply

allochthon Jun. 1 at 6:28 PM

$PHAT fair point — the bridge between our quarter end numbers is probably down to restocking activity which could be 10%ish of total Rx. That doesn’t get reported in these weekly IQVIA numbers and I didn’t factor it in. Good points by others on cash pay and accounting tailwinds, too. Definitely a comfortable risk/reward to add to all the way down here

0 · Reply

Market Cap	804.74M
Revenue (ttm)	175.11M
Net Income (ttm)	-221.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-126.35%
Debt to Equity Ratio	-0.49

Volume	1,038,000
Avg Vol	1,273,464
Day's Range	N/A - N/A
Shares Out	79.76M
Stochastic %K	34%
Beta	0.50
Analysts	Strong Sell
Price Target	$23.70